Postmenopausal women with severe osteoporosis can safely be prescribed the anabolic drug romosozumab as a first-line therapy, according to updated guidance from the US Endocrine Society.

The peak body made the decision to add the drug to its guidelines after reviewing a meta-analysis and two large clinical trials assessing its efficacy against placebo and the osteoporosis drug alendronate.